- In March 2023, Perrigo Company plc obtained final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) concerning acetaminophen and ibuprofen tablets, formulated at 250 mg/125 mg. These medications are commonly utilized in the management of osteonecrosis due to their analgesic and anti-inflammatory properties. This approval not only enhances Perrigo's product portfolio but also provides patients with more accessible treatment options for this condition
- In March 2023, AFT Pharmaceuticals received FDA approval for Combogesic, a combination of acetaminophen and ibuprofen, aimed at the short-term management of mild to moderate acute pain. This dual-action formulation is particularly beneficial for patients suffering from osteonecrosis, as both medications effectively alleviate pain and inflammation associated with the condition. The approval of Combogesic enhances the treatment options available for those in need of effective pain relief for osteonecrosis and other related ailments
- In May 2022, Regrow Biosciences was granted Orphan Drug Designation (ODD) for OSSGROW by both the U.S. FDA and the European Medicines Agency (EMA). This designation is significant as it recognizes OSSGROW's potential to address the unmet medical needs of patients suffering from osteonecrosis. By receiving ODD status, the drug is positioned to benefit from various incentives aimed at expediting its development and approval process, ultimately improving treatment options for those affected by this condition
- In April 2021, ECI Pharmaceuticals LLC entered into an exclusive distribution agreement with AiPing Pharmaceuticals, Inc. This partnership allows AiPing to manage the sales, marketing, and distribution of ibuprofen tablets in 400 mg, 600 mg, and 800 mg dosages, as well as folic acid 1 mg tablets throughout the U.S. This collaboration aims to enhance the availability of these medications, which are crucial for pain management and overall health
- In February 2021, Additive Orthopaedics obtained FDA approval for its total talus replacement implant, classified as a humanitarian-use device. This innovative implant is specifically designed for the talus spacer, offering a patient-specific treatment solution for avascular necrosis of the talus in the U.S. The approval marks a significant advancement in addressing this challenging condition, providing patients with tailored surgical options for improved outcomes.
Frequently Asked Questions
The market is segmented based on Segmentation, By Therapy (Stem Cell Therapy and Joint Replacement Therapy), Drug Type (Non-Steroidal Anti-Inflammatory Drugs, Blood Thinners, and Others), Treatment (Medication and Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Direct, Online Pharmacy, Retailers and Others), End-User (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2031
.
The Global Osteonecrosis Treatment Market size was valued at USD 268.20 USD Billion in 2023.
The Global Osteonecrosis Treatment Market is projected to grow at a CAGR of 6.7% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
